PYXIS ONCOLOGY INC (PYXS)
US7473241013 - Common Stock
We assign a fundamental rating of 2 out of 10 to PYXS. PYXS was compared to 565 industry peers in the Biotechnology industry. PYXS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PYXS does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year PYXS has reported negative net income.
PYXS had a negative operating cash flow in the past year.
In the past 5 years PYXS always reported negative net income.
In the past 5 years PYXS always reported negative operating cash flow.
1.2 Ratios
With a decent Return On Assets value of -29.37%, PYXS is doing good in the industry, outperforming 69.52% of the companies in the same industry.
The Return On Equity of PYXS (-37.32%) is better than 74.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -29.37% | ||
| ROE | -37.32% | ||
| ROIC | N/A |
ROA(3y)-42.24%
ROA(5y)-53.3%
ROE(3y)-54.28%
ROE(5y)-76.2%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for PYXS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
PYXS has more shares outstanding than it did 1 year ago.
There is no outstanding debt for PYXS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
PYXS has an Altman-Z score of 0.66. This is a bad value and indicates that PYXS is not financially healthy and even has some risk of bankruptcy.
With a decent Altman-Z score value of 0.66, PYXS is doing good in the industry, outperforming 65.95% of the companies in the same industry.
PYXS has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.00, PYXS is in line with its industry, outperforming 49.55% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.66 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 7.33 indicates that PYXS has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 7.33, PYXS is in the better half of the industry, outperforming 69.70% of the companies in the same industry.
PYXS has a Quick Ratio of 7.33. This indicates that PYXS is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 7.33, PYXS is doing good in the industry, outperforming 69.70% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.33 | ||
| Quick Ratio | 7.33 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 48.90% over the past year.
EPS 1Y (TTM)48.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.64%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, PYXS will show a decrease in Earnings Per Share. The EPS will decrease by -1.18% on average per year.
PYXS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 201.00% yearly.
EPS Next Y43.95%
EPS Next 2Y15.97%
EPS Next 3Y9.16%
EPS Next 5Y-1.18%
Revenue Next Year7949.25%
Revenue Next 2Y-41.42%
Revenue Next 3Y192.4%
Revenue Next 5Y201%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for PYXS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PYXS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.97%
EPS Next 3Y9.16%
5. Dividend
5.1 Amount
PYXS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PYXIS ONCOLOGY INC
NASDAQ:PYXS (11/20/2024, 8:00:00 PM)
Premarket: 2.5 -1.32 (-34.55%)3.82
-0.34 (-8.17%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap226.98M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -29.37% | ||
| ROE | -37.32% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 7.33 | ||
| Quick Ratio | 7.33 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)48.9%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y43.95%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y